Big Plans and 40 Years of Experience
News Jun 30, 2015
Rudi Vollmer (61) has become the new Technical Managing Director of Greiner Bio-One GmbH. Vollmer, formerly head of production at the Frickenhausen site, replaces Rainer Perneker, who has left the management team in Germany to focus on the business as Divisional Manager of the Greiner Bio-One International GmbH.
As a member of the Greiner Bio-One GmbH Germany management team, Rudi Vollmer is now responsible for production and technology. Heinz Schmid stays as head of the sales division and the management spokesperson. Georg Heftberger remains responsible for commercial and business operations. “I have extensive plans for working with the other two Managing Directors to build the success of Greiner Bio-One GmbH in Frickenhausen,” says Vollmer, whose responsibilities also cover the key areas of quality management, project management and design.
Anniversary - total of 40 years with Greiner
Rudi Vollmer started his career at Greiner (Labortechnik) in Nürtingen in 1975 - in the field of toolmaking. In 1978, he qualified and was taken on as a production foreman. He moved to the newly built site in Frickenhausen in 1988, where he took over management of the high-throughput screening and immunology production divisions three years later. When project management was introduced in March 2006, Rudi Vollmer took on full management of production. He celebrated 40 years at the company in April 2015.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018